{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-020476","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2022-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.314335+00:00","generated_at":"2026-06-25T11:30:04.648864+00:00","sec_items":[],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"aTyr Pharma launches Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis, citing positive Phase 1b/2a data","bullets":["Phase 3 EFZO-FIT will enroll 264 patients; primary endpoint is steroid reduction; secondary endpoints include lung function and symptoms.","Phase 1b/2a data showed dose-dependent improvements; 5.0 mg/kg group had three patients completely taper off steroids.","Efzofitimod demonstrated control of inflammatory biomarkers (IFN-γ, IL-6, IP-10, MCP-1, TNFa) over 24 weeks.","Two higher doses (3.0 and 5.0 mg/kg) improved lung function measures (FVC, DLCO) vs placebo.","Trial expected to initiate Q3 2022; Phase 1b/2a results presented at ATS 2022 conference May 17."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-020476","json":"https://secwatch.observer/filing/0001564590-22-020476.json","markdown":"https://secwatch.observer/filing/0001564590-22-020476.md","text":"https://secwatch.observer/filing/0001564590-22-020476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022020476/0001564590-22-020476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022020476/life-8k_20220516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T11:30:04.648864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}